NO20053761L - Parenterale peptidformuleringer for behandling av systemisk lupus erythematosus. - Google Patents

Parenterale peptidformuleringer for behandling av systemisk lupus erythematosus.

Info

Publication number
NO20053761L
NO20053761L NO20053761A NO20053761A NO20053761L NO 20053761 L NO20053761 L NO 20053761L NO 20053761 A NO20053761 A NO 20053761A NO 20053761 A NO20053761 A NO 20053761A NO 20053761 L NO20053761 L NO 20053761L
Authority
NO
Norway
Prior art keywords
lupus erythematosus
systemic lupus
composition
treatment
peptide
Prior art date
Application number
NO20053761A
Other languages
English (en)
Other versions
NO20053761D0 (no
Inventor
Ety Klinger
Sharon Cohen-Vered
Esmira Nftali
Adrian Gilbert
Vera Weinstein
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20053761D0 publication Critical patent/NO20053761D0/no
Publication of NO20053761L publication Critical patent/NO20053761L/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer en farmasøytisk sammensetning som omfatter en vandig bærer; fra 0,1 mg/ml til 20 mg/ml av sammensetningen av et farmasøytisk akseptabelt salt av et peptid som har den strukturelle formelen NH-GIy Tyr Tyr Tip Ser Trp Ile Arg Gin Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-COOH; og et substituert ^«cyklodekstrin i en mengde som er effektiv for å løse peptidet i den vandige bæreren, hvor sammensetningen har en pH mellom 4 og 9, en prosess for tillaging og en fremgangsmåte for å forbedre symptomer til systemisk lupus erytematose (SLE) i et humant individ som omfatter å gi til det humane individet den farmasøytiske sammensetningen.
NO20053761A 2003-01-14 2005-08-08 Parenterale peptidformuleringer for behandling av systemisk lupus erythematosus. NO20053761L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43995003P 2003-01-14 2003-01-14
PCT/US2004/000955 WO2004064788A2 (en) 2003-01-14 2004-01-14 Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus

Publications (2)

Publication Number Publication Date
NO20053761D0 NO20053761D0 (no) 2005-08-08
NO20053761L true NO20053761L (no) 2005-10-12

Family

ID=32771763

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053761A NO20053761L (no) 2003-01-14 2005-08-08 Parenterale peptidformuleringer for behandling av systemisk lupus erythematosus.

Country Status (18)

Country Link
US (2) US7294687B2 (no)
EP (1) EP1587525A4 (no)
JP (1) JP2006516034A (no)
KR (1) KR20050100616A (no)
CN (1) CN1761477A (no)
AU (1) AU2004206844A1 (no)
BR (1) BRPI0406737A (no)
CA (1) CA2513331A1 (no)
CO (1) CO5640149A2 (no)
CR (1) CR7936A (no)
EA (1) EA008438B1 (no)
EC (1) ECSP055960A (no)
MX (1) MXPA05007552A (no)
NO (1) NO20053761L (no)
NZ (1) NZ541659A (no)
UA (1) UA83816C2 (no)
WO (1) WO2004064788A2 (no)
ZA (1) ZA200506205B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
DK1594434T3 (da) * 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
CA2513331A1 (en) * 2003-01-14 2004-08-05 Teva Pharmaceutical Industries Ltd Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
DE102004043750A1 (de) * 2004-09-10 2006-03-30 Sanofi-Aventis Deutschland Gmbh Formulierungen des Peptids p277 oder dessen Varianten mit optimierter Stabilität
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
EP2124883A2 (en) * 2006-12-12 2009-12-02 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations and methods for making the same
EP2121139B1 (en) * 2007-01-16 2012-10-10 BiPar Sciences, Inc. Formulations for cancer treatment
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
PL3702374T3 (pl) 2012-02-15 2022-11-21 Cydex Pharmaceuticals, Inc. Sposób wytwarzania pochodnych cyklodekstryny
KR102112119B1 (ko) 2012-10-22 2020-05-19 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
US10851184B2 (en) 2014-08-22 2020-12-01 Cydex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
AU2018205885A1 (en) 2017-01-05 2019-06-27 Yeda Research And Development Co. Ltd. Peptides for treating Sjogren's syndrome
CN110960442B (zh) * 2019-12-17 2023-03-31 珠海冀百康生物科技有限公司 一种多肽包封物的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60184098A (ja) * 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5126249A (en) 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
US6613536B1 (en) 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
IL113159A0 (en) 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
IL120503A0 (en) 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
US20020054872A1 (en) 1997-03-20 2002-05-09 Yaakov Naparstek Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
EP1045836B1 (en) 1997-12-18 2008-03-05 Boehringer Ingelheim Pharmaceuticals Inc. Pyridones as src family sh2 domain inhibitors
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US7114005B2 (en) 2002-02-05 2006-09-26 Cisco Technology, Inc. Address hopping of packet-based communications
CA2513331A1 (en) * 2003-01-14 2004-08-05 Teva Pharmaceutical Industries Ltd Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
DK1594434T3 (da) * 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus

Also Published As

Publication number Publication date
WO2004064788A3 (en) 2005-03-24
US20080287366A1 (en) 2008-11-20
EP1587525A4 (en) 2008-09-10
EA008438B1 (ru) 2007-06-29
AU2004206844A1 (en) 2004-08-05
UA83816C2 (ru) 2008-08-26
CR7936A (es) 2006-05-31
EA200501129A1 (ru) 2006-02-24
US7294687B2 (en) 2007-11-13
US20040180059A1 (en) 2004-09-16
KR20050100616A (ko) 2005-10-19
CN1761477A (zh) 2006-04-19
ZA200506205B (en) 2006-12-27
NZ541659A (en) 2007-05-31
JP2006516034A (ja) 2006-06-15
MXPA05007552A (es) 2006-05-19
CA2513331A1 (en) 2004-08-05
BRPI0406737A (pt) 2005-12-20
CO5640149A2 (es) 2006-05-31
WO2004064788A2 (en) 2004-08-05
ECSP055960A (es) 2006-04-19
EP1587525A2 (en) 2005-10-26
NO20053761D0 (no) 2005-08-08

Similar Documents

Publication Publication Date Title
NO20053761L (no) Parenterale peptidformuleringer for behandling av systemisk lupus erythematosus.
CR7938A (es) Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico
ES2387848T3 (es) Composiciones para el tratamiento de trastornos gastrointestinales
US5604203A (en) Analogs of peptide YY and uses thereof
ES2523858T3 (es) Fragmentos de VIP y composiciones de los mismos
CA2729938A1 (en) New insulin analogues of prolonged activity
ES2632787T3 (es) Análogos agonistas del receptor opioide mu de las endomorfinas
US20220118105A1 (en) CD38 Antibody Drug Conjugate
CN113194983A (zh) 用于治疗病毒感染的组合物及方法
RS54215B1 (en) COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
US20070099841A1 (en) Prodrugs of T3 and T4 with enhanced bioavailability
CA2649360A1 (en) Mono and di-substituted oxycodone compounds and compositions
SK11242002A3 (sk) Zlúčenina, spôsob prípravy zlúčeniny, farmaceutický prostriedok a spôsob liečenia rakoviny
AU2001277908A1 (en) Medicinal uses of mu-opioid receptor agonists
CN115697380A (zh) 用于治疗甲状旁腺功能减退症的pth类似物
JP6656661B2 (ja) プレキシンの結合調節剤
US20060189536A1 (en) Treating the effects of nicotine
CA2374270A1 (en) Labeled neurotensin derivatives
KR19990044554A (ko) 펩티드 유도체
WO1999033864A1 (fr) Derives peptidiques
US5071836A (en) Competitive gonadoliberin antagonists
KR19990044553A (ko) 펩티드 유도체
WO2007145208A1 (ja) ペプチド誘導体
JP7437578B2 (ja) 新規オピオイドペプチド、その糖鎖付加体及びそれらを含む医薬組成物
JPH06509571A (ja) タキキニン拮抗薬としての環状ヘキサペプチドの製法およびその薬学的化合物

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application